Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
- PMID: 31165801
- DOI: 10.1039/c8cs00896e
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Abstract
In recent years, conventional treatments including surgery, chemotherapy and radiotherapy have been the main approaches in tumour therapy. Cancer immunotherapy is a new therapeutic modality to fight cancer by harnessing the power of patients' own immune system. Ongoing research related to these therapies has demonstrated their advantages and intrinsic limitations. Nanomaterial-based platforms are utilized in these emerging fields. In particular, a combination of other treatment methods with cancer immunotherapy to achieve precision medicine and prevent recurrence and metastasis, could improve patients' outcome. The combined multiple treatments have superior efficacy to any monotherapy alone in producing improved anti-cancer activity. Therefore, it's necessary to summarise research advances in nanomaterial-based combination cancer immunotherapy contributing to clinical transformation. This review is based on the principles of cancer immunotherapy and the combined treatment design reflected by advances in materials science, including the structures of nanoplatforms and their underlying mechanisms towards cancer. The ultimate goals are to stimulate the design of better strategies for versatile use in the future based on biomaterial engineering methods to enhance the efficacy of combined cancer treatments, and to provide new ideas for the prospects of a synergistic cancer combination immunotherapy for clinical application transformation.
Similar articles
-
Recent Advances in Nanomaterial-Assisted Combinational Sonodynamic Cancer Therapy.Adv Mater. 2020 Nov;32(47):e2003214. doi: 10.1002/adma.202003214. Epub 2020 Oct 16. Adv Mater. 2020. PMID: 33064322 Review.
-
Adapting conventional cancer treatment for immunotherapy.J Mol Med (Berl). 2016 May;94(5):489-95. doi: 10.1007/s00109-016-1393-4. Epub 2016 Feb 24. J Mol Med (Berl). 2016. PMID: 26910191 Review.
-
Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?Acta Biomater. 2021 Apr 15;125:1-28. doi: 10.1016/j.actbio.2021.02.030. Epub 2021 Feb 24. Acta Biomater. 2021. PMID: 33639310 Review.
-
Emerging Opportunities and Challenges in Cancer Immunotherapy.Clin Cancer Res. 2016 Apr 15;22(8):1845-55. doi: 10.1158/1078-0432.CCR-16-0049. Clin Cancer Res. 2016. PMID: 27084738 Free PMC article. Review.
-
The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors.Integr Cancer Ther. 2019 Jan-Dec;18:1534735419876345. doi: 10.1177/1534735419876345. Integr Cancer Ther. 2019. PMID: 31522574 Free PMC article. Review.
Cited by
-
Role of Functionalized Peptides in Nanomedicine for Effective Cancer Therapy.Biomedicines. 2024 Jan 16;12(1):202. doi: 10.3390/biomedicines12010202. Biomedicines. 2024. PMID: 38255307 Free PMC article. Review.
-
Multifunctional nanoparticle-mediated combining therapy for human diseases.Signal Transduct Target Ther. 2024 Jan 1;9(1):1. doi: 10.1038/s41392-023-01668-1. Signal Transduct Target Ther. 2024. PMID: 38161204 Free PMC article. Review.
-
Synergistically Enhancing Immunotherapy Efficacy in Glioblastoma with Gold-Core Silica-Shell Nanoparticles and Radiation.Int J Nanomedicine. 2023 Dec 14;18:7677-7693. doi: 10.2147/IJN.S440405. eCollection 2023. Int J Nanomedicine. 2023. PMID: 38111846 Free PMC article.
-
Gel/hydrogel-based in situ biomaterial platforms for cancer postoperative treatment and recovery.Exploration (Beijing). 2023 May 31;3(5):20220173. doi: 10.1002/EXP.20220173. eCollection 2023 Oct. Exploration (Beijing). 2023. PMID: 37933278 Free PMC article. Review.
-
A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance.J Ovarian Res. 2023 Sep 6;16(1):186. doi: 10.1186/s13048-023-01260-9. J Ovarian Res. 2023. PMID: 37674251 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
